Neuromodulation for Epilepsy.

Area of Science:

• Neurology
• Neurosurgery
• Biomedical Engineering

Background:

• Epilepsy surgery aims to reduce or eliminate seizures using various procedures.
• Intraoperative neurophysiology aids in mapping epileptic foci and critical brain areas.
• Resection is not feasible for drug-resistant epilepsy with diffuse, multifocal, or eloquent onset seizures.

Purpose of the Study:

• To explore neuromodulation as a palliative treatment for drug-resistant epilepsy.
• To review FDA-approved neuromodulation devices for epilepsy management.
• To discuss the efficacy and benefits of neuromodulation therapies.

Main Methods:

• Review of neuromodulation techniques for epilepsy.
• Description of FDA-approved devices: vagus nerve stimulation, deep brain stimulation (anterior nucleus of the thalamus), and responsive neurostimulation.
• Analysis of seizure reduction rates and temporal benefits.

Main Results:

• Neuromodulation techniques are palliative, unlike curative resective surgery.
• Three FDA-approved neuromodulation modalities exist for epilepsy treatment.
• Patients experience significant seizure reduction (>50%), with benefits increasing over time.

Conclusions:

• Neuromodulation provides a valuable alternative for drug-resistant epilepsy when resection is not possible.
• Vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation offer palliative seizure control.
• These therapies demonstrate both acute and chronic benefits, improving seizure burden over time.